Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Filed Mar 11, 2022 · 10-K · 70 days after period end · 0001171843-22-001790
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $35.82M | $32.69M | $29.77M | $26.96M |
| Net Income | -$5.79M | -$15.66M | $4.05M | $7.72M |
| EPS Diluted | — | -$1.10 | $0.28 | $0.54 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 11, 2022 · 70 d after period end
